IFCC Looking Outwards: International Clinical Liaison

Howard Morris (AU) – Vice President on behalf of IFCC Executive Board
Why do we want Clinical Liaisons?

• Laboratory Medicine is often considered the ‘Cinderella’ discipline of medical practice

• IFCC Mission

  “We will aim to communicate effectively with our members, other healthcare providers and the public to ensure knowledge of our excellent scientific and educational achievements.”

• Liaisons between National Societies and clinical societies certainly occur but IFCC believes this is an area we should expand and has been included in our 2012 – 2014 Strategic Plan
What have we been doing? - 1

- Largely relationships with other organisations are the responsibility of the President
- The President established the Task Force – International Clinical Liaisons (Chair Ian Watson (UK) 2009 – 2011)
- It completed work for improving communications within and outside the IFCC by recommending procedures for internal communication &
- Identified requirements for improved communication within the medical professions with preliminary work commencing on a strategy
What have we been doing? - 2

- Currently we have collaborations with a wide range of clinical societies
- These occur at the levels of the EB as well as within the Scientific and Education and Management Divisions, which are project based
- We also host symposia sponsored by clinical societies at our WorldMedLab/ICCC congresses

For example in Berlin 2011 the World Association of Societies of Pathology and Laboratory Medicine (WASPaLM) and International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) sponsored symposia
Who are we currently working with?

IFCC has a wide range of collaborators including the leading metrology (BIPM) and accreditation (ILAC) organisations and the leading chemistry organisation (IUPAC).

Leading international clinical organisations include:

- World Health Organisation including National Institute for Biological Standards and Control
- WASPaLM
- International Society for Thrombosis and Hemostasis
- IATDMCT
Who are we currently working with?

Current Scientific and Education and Management Divisions C and WG clinical society collaborators – (13)

• Consortium on Clinical Laboratory Genetics and Genomics Standards;
• Human Proteome Organisation;
• International Diabetes Federation,
• International Society for Oncology and Biomarkers;
• IGF Society and Growth Hormone Research Society;
• International Osteoporosis Foundation
• European Association of Diabetes Societies,
• American Diabetes Association,
• Japanese Diabetes Society;
• American Thyroid Association,
• American Association of Clinical Endocrinologists;
• National Kidney Disease Education Program;
What is our current goal?

At this time many of our collaborators participate in symposia presented at IFCC World and Regional Congresses

As a first step
We want to redress the balance

Our aim is for the work of IFCC collaborations to be reported at Congresses organised by our clinical collaborators
What is the next step?

Write to all Chairs of C’s, WG’s and TF’s collaborating with clinical societies asking them to:

• Identify a suitable congress/ conference being organised by their collaborating society during 2014/2015/2016 together with your clinical collaborator

• Prepare a scientific programme for a symposium reporting their work and its clinical application

• Identify the Chair of the scientific program organising committee

• Submit the proposal for a symposium
Conclusion:

The EB will maintain a record of applications and acceptances to monitor the outcome from this aspect of the Strategic Plan.
Thank You

We Look Forward to Your Help in Taking the IFCC Out to our Clinical Colleagues